Project plan published for benefit assessment of motor-driven movement splints (CPM) after interventions on the knee joint and on the shoulder joint by IQWiG

11

Dec 2017

Motor-driven movement sprints, also called continuous passive motion (CPM) splints, are used in the conservative treatment or after surgical interventions on joint structures. This is intended to improve or restore joint mobility, to prevent joint stiffening and to promote healing.

In September 2016, the Federal Joint Committee (G-BA) commissioned the German Institute for Quality and Efficiency in Health Care (IQWiG) with the assessment of the use of a (domestic) application of CPM as part of a conservative treatment or after surgery on the knee or shoulder joint. The aim is to assess the benefit of the method with respect to patient-relevant outcomes compared to no treatment, sham treatment, or treatment with any CPM comparison intervention that meets the clinical standard.

After the publication of the preliminary project plan in the end of 2016, the IQWiG invited organizations, institutions, and industry to comment on the planned assessment. Written statements were submitted by:

- Institute for empirical health economy (IFEG)

- ORMED GmbH and S&U Medizintechnik GmbH (manufacturers)

- Association CPM Therapy (Verband CPM Therapie e. V.)

IQWiG evaluated the arguments and presented a review in the appraisal of comments. Arguments that were considered by IQWiG as scientifically valid arguments in relation to background and methods are reflected in the updated project plan.

IQWiG regularly calls for opinions or statements by interested parties on its website. In the context of benefit assessments, this gives an important opportunity to manufacturers for impacting the planned evaluation.

The project plan by IQWiG is available in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

09

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Read more

03

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Read more

07

Feb 2022

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

Read more

28

Jan 2022

On December 26, 2021, the new health app was introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 28 health apps are now available at the DiGA Directory.

Read more